Dr. Shi has 25 years of experience in life science commercial operations, business development and investment. He currently focuses on investing in diagnostics and medical devices in China. He has led commercial operations at QIAGEN in Asia Pacific for ten years. Previously he was either a founding member of or held senior positions at Aura Partners, Bridge Pharmaceuticals, Genospectra, and A. M. Pappas & Associates. He was also a faculty member at National University of Singapore, School of Medicine and a cancer research scientist at Merck & Co.
Dr. Shi currently serves as Deputy Secretary-General of Chinese In-Vitro Diagnostics Industry Association and is a member of the China Board and Executive Committee of the Advanced Medical Technology Association (AdvaMed). He also serves on the board of Bayhelix, a global association of Chinese life science business executives.
Dr. Shi obtained a Ph.D. and an MS degree from the University of Rochester, New York, and a BS from the University of Science and Technology of China.